Press Releases

The SCOTUS decision represents a departure from judicial and PTO precedent supporting patentability of DNA molecules. The decision could create business uncertainty for a range of inventions.

The 10th Annual World Congress on Industrial Biotechnology will host the Clean Tech Investor Sessions featuring innovative industrial biotechnology companies selected to present to an elite audience of investors and analysts. 

There are several aspects of this report that deserve further scrutiny.

BIO applauded the Senate version of the Farm Bill, which includes robust mandatory funding for Energy Title programs and eligibility for renewable chemicals.

BIO and Delaware Biocommend the State Senate for introducing legislation designed to  address the regulatory issues related to the interchangeability of biological medicines.

Oregon Governor John Kitzhaber signed legislation on Thursday, June 6 designed to address the regulatory issues related to the interchangeability of biological medicines.

Reps. Marcy Kaptur (D-Ohio), Bruce Braley (D-Iowa) and 11 original co-sponsors introduced the Rural Energy Investment Act, to provide robust mandatory funding and extend eligibility to renewable chemicals in Farm Bill renewable energy and energy efficiency programs.

House Bill 365, signed by Governor Rick Scott, contains four of BIO’s five principles on biologic product substitution

The 2013 BIO World Congress on Industrial Biotechnology this June 16-19 in Montreal, Canada at the Palais des congrès de Montréal will mark the event’s 10th anniversary. 

Florida's repeal of the state Renewable Fuel Standard could chill investment, innovation and job creation within the state's biotechnology industry.

The industrial biotech sector supports reform of the Toxic Substances Control Act that promotes innovation in renewable chemicals, which consumers can be confident are cleaner, healthier and safer.

BIO submitted comments in response to a House Energy & Commerce white paper on the environmental benefits of biofuels, emphasizing that biofuels' environmental profile continues to improve.

Rx Response elevates to Alert status to address potential impact from Moore tornado on supply chain.

BIO invites leaders from the biotechnology, chemical and agricultural industries to submit proposals and abstracts for panels, individual papers and posters for the 2013 Pacific Rim Summit on Industrial Biotechnology and Bioenergy. 

BIO welcomes the opportunity to comment on EPA's proposed amendments and clarifications to the Renewable Fuel Standard. BIO will work with EPA to finalize new pathways for advanced and cellulosic biofuels, which are needed to meet the goals of the RFS.

CSBI encourages a tax code that promotes economic growth and creates jobs.

House Agriculture Committee Democrats, led by Rep. Tim Walz (D-Minn.), offered an amendment to the Farm Bill that would provide mandatory funding to energy title programs.

H.R. 701 sets a deadline to complete rule-making on Regulation A reforms.

In a bipartisan vote, the Senate Agriculture, Nutrition and Forestry committee passed a Farm Bill that included robust mandatory funding for energy programs and eligibility for renewable chemicals.

H.R. 1952 will stimulate trading for small public companies.

BIO welcomes the unanimous Supreme Court decision in Bowman v. Monsanto, in which the Court confirms that biotechnology seed is entitled to the same protections as other inventions under the patent law.

The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) announced today that the Agency plans to prepare two separate environmental impact statements (EIS) on crops genetically engineered to be resistant to the herbicides known as 2,4 dichlorophenoxyacetic acid (2,4-D) and Dicamba. 

A letter sent to USDA Secretary Tom Vilsack and Acting U.S. Trade Representative Demetrios Marantis by 26 Senators urges continued attention by the U.S. Government on international trade issues associated with the use of agricultural biotechnology.

Pediatric research is essential to study the effects of new therapeutics in children.